How to Get Addyi (Flibanserin) in Arizona

What Is Flibanserin and Why Does It Require a Special Prescribing Process?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval in August 2015 [1], and the agency simultaneously required a Risk Evaluation and Mitigation Strategy (REMS) program because of the drug's interaction with alcohol and its potential to cause severe hypotension and syncope. Every prescriber who writes for flibanserin must complete REMS certification before the prescription can be dispensed [2].

HSDD is defined as persistently low sexual desire that causes marked distress or interpersonal difficulty and is not explained by another medical condition, a medication, or a relationship problem [3]. Epidemiological data from the National Health and Social Life Survey and subsequent analyses suggest roughly 10 percent of U.S. women meet criteria for distressing low desire, though prevalence estimates vary by study design [4].

The BEGONIA trial (N=1,378, published J Sex Med 2014) showed that premenopausal women assigned to flibanserin 100 mg at bedtime reported a statistically significant increase in satisfying sexual events compared with placebo over 24 weeks, with a mean difference of approximately 0.5 events per 28 days (P<0.001) [5]. That modest but consistent signal across multiple Phase 3 studies formed the basis of the FDA's benefit-risk determination [1].

Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist in the prefrontal cortex, a mechanism distinct from phosphodiesterase inhibitors used in male sexual dysfunction [6]. Because it is not a hormone, it is not subject to the same contraindications as estrogen-containing therapies, but the alcohol restriction and CYP3A4 interaction profile do demand careful patient selection.

Who Can Prescribe Addyi in Arizona?

Any licensed Arizona prescriber who completes REMS training may write for flibanserin. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Arizona grants NPs full practice authority under A.R.S. § 32-1606, meaning they can prescribe independently without physician oversight [7]. PAs prescribe under a supervising physician agreement but face no special state restriction on flibanserin specifically.

The REMS certification is straightforward. A prescriber visits the Addyi REMS website, reviews a short training module on the alcohol interaction and syncope risk, and attests to their understanding. There is no examination and no renewal interval tied to a fixed calendar. Certification is linked to the prescriber's DEA or NPI number and is checked by the dispensing pharmacy before dispensing.

Telehealth providers licensed in Arizona are subject to the same REMS requirement. Arizona adopted strong telehealth parity rules under A.R.S. § 36-3602, and the state Medical Board has clarified that a valid prescriber-patient relationship can be established via synchronous audio-video visit, allowing flibanserin to be prescribed remotely [8]. Asynchronous (store-and-forward) consults alone are generally insufficient to meet the standard-of-care threshold for a new controlled-substance-adjacent prescription.

How to Get an Addyi Prescription in Arizona: Step by Step

Getting flibanserin in Arizona follows a predictable sequence regardless of whether the visit is in-person or via telehealth.

Step 1. Choose a REMS-certified prescriber or telehealth platform. Several national telehealth platforms serving Arizona have physicians and NPs already REMS-certified for flibanserin. Confirm REMS status before booking. In-person options include gynecologists, women's health internists, and psychiatrists comfortable with sexual medicine.

Step 2. Complete intake paperwork. Expect questions about alcohol use frequency and quantity, current medications (especially CYP3A4 inhibitors such as fluconazole, ketoconazole, and some macrolide antibiotics), liver function history, and history of low blood pressure.

Step 3. Attend the clinical visit. The prescriber will confirm the HSDD diagnosis using validated instruments such as the Female Sexual Function Index (FSFI) [9] or the Female Sexual Distress Scale-Revised (FSDS-R). A score below 26.55 on the FSFI suggests sexual dysfunction [9]. Distress must be present; low desire without distress does not meet the diagnostic threshold for HSDD [3].

Step 4. Address lab work if indicated. Flibanserin does not have a mandatory pre-treatment laboratory panel in its FDA label [1]. A prescriber may order a comprehensive metabolic panel (CMP) if liver disease is suspected, because hepatic impairment significantly elevates flibanserin plasma levels and is listed as a contraindication [2]. No routine CBC or hormone panel is mandated before prescribing.

Step 5. Receive the prescription and select a pharmacy. The prescription is sent to a REMS-certified pharmacy. The patient also signs a Patient-Prescriber Agreement form acknowledging the alcohol warning. Major retail chains including CVS, Walgreens, and Fry's (Kroger) in Arizona carry or can order flibanserin. Licensed 503A compounding pharmacies in Arizona may also compound flibanserin for patients with documented intolerance to excipients in the branded tablet.

Step 6. Begin therapy and follow up. The FDA label recommends reassessing response at 8 weeks [1]. If no improvement in satisfying sexual events or desire is observed, discontinuation is recommended.

What Labs Are Needed Before Starting Addyi?

No mandatory pre-treatment labs are specified in the FDA-approved prescribing information for flibanserin [1]. This distinguishes it from testosterone therapy or hormonal contraceptives, which often carry baseline lab requirements. However, prescribers routinely order a hepatic function panel when the patient has a history of alcohol use disorder, hepatitis, or other liver disease, because the drug's CYP2C19 metabolism is substantially affected by hepatic impairment [2].

Specifically, flibanserin exposure (AUC) increases approximately 4.5-fold in patients with mild hepatic impairment, and the drug is contraindicated in moderate-to-severe hepatic impairment [2]. A baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) check takes less than 24 hours to result and removes any ambiguity before prescribing.

Some clinicians order a thyroid-stimulating hormone (TSH) test to rule out hypothyroidism as a reversible cause of low libido [10]. The Endocrine Society guidelines on female sexual dysfunction note that thyroid disease should be excluded before attributing desire problems to HSDD [10]. This is not an FDA requirement but reflects prudent clinical practice.

A pregnancy test is warranted if there is any possibility of pregnancy, because flibanserin is not studied in pregnant women and is classified FDA Pregnancy Category data is limited [1].

Telehealth Options for Addyi in Arizona

Arizona telehealth parity law requires most insurers to reimburse synchronous telehealth visits at the same rate as equivalent in-person encounters, which has expanded access considerably [8]. Several national platforms specifically list flibanserin prescribing as part of their women's sexual health services. Patients in Tucson, Scottsdale, Flagstaff, and rural areas of Arizona that lack local sexual medicine specialists benefit most from this route.

A standard telehealth workflow for flibanserin runs as follows. The patient completes a digital health history form, uploads any relevant prior records, and schedules a live video visit typically lasting 20 to 40 minutes. The prescriber reviews contraindications, confirms the HSDD diagnosis, obtains verbal consent for the REMS Patient-Prescriber Agreement (with a digital signature collected through the platform), and sends the prescription electronically to the patient's chosen pharmacy.

The HealthRX clinical team uses a four-domain screening checklist before approving flibanserin via telehealth: (1) confirmation of premenopausal status or documentation of menopause status if there is uncertainty; (2) a validated FSFI or FSDS-R score reviewed by the prescriber rather than self-reported in free text; (3) an explicit alcohol-use disclosure with a written commitment to abstain during treatment; and (4) a current medication reconciliation cross-checked against the CYP3A4 inhibitor list. Prescribers who skip any of these four steps expose patients to the syncope risk the REMS program was designed to mitigate.

Average time from completed telehealth visit to delivery of the first 30-tablet supply at an Arizona address runs 3 to 7 business days when the prescription is sent to a retail pharmacy with stock on hand. Specialty mail-order pharmacies serving Arizona may run 5 to 10 business days.

Insurance Coverage and Prior Authorization in Arizona

Arizona Medicaid (AHCCCS) does not cover flibanserin. Private commercial insurers in Arizona vary widely. UnitedHealthcare, Aetna, Blue Cross Blue Shield of Arizona, and Cigna all list flibanserin as a non-preferred specialty drug on their formularies, generally requiring prior authorization (PA) before covering any portion of the cost [11].

A typical PA request for flibanserin in Arizona requires the following documentation: (1) a confirmed diagnosis code of F52.0 (hypoactive sexual desire disorder, per ICD-10-CM) [12]; (2) documentation that the patient is premenopausal; (3) evidence that the prescriber is REMS-certified; (4) confirmation that the patient has been counseled on alcohol abstinence; and (5) in some plans, documentation of a trial of psychotherapy or sex therapy, though this requirement is not universal.

Without insurance coverage, the branded Addyi 100 mg, 30-tablet supply retails for approximately $400 to $800 per month at Arizona pharmacies. Sprout Pharmaceuticals offers a savings card that may reduce out-of-pocket cost for commercially insured patients. GoodRx and similar discount programs apply to the generic flibanserin that became available after 2019, reducing cash-pay cost to the $60 to $150 range depending on the pharmacy and the specific coupon.

Arizona 503A Compounding Pharmacies and Flibanserin

State-licensed 503A compounding pharmacies in Arizona may prepare customized flibanserin formulations for individual patients when there is a documented clinical need, such as an allergy to an excipient in the branded tablet or a requirement for an alternative delivery form [13]. The FDA regulates compounded versions differently than manufactured drugs; a 503A pharmacy compounds only on receipt of a valid patient-specific prescription and does not manufacture in bulk for general sale [13].

Flibanserin is not on the FDA's 503A Bulks List, which means it can only be compounded from a commercially available API (active pharmaceutical ingredient) for a specific patient, not from a bulk chemical for stock [14]. Arizona pharmacies that compound flibanserin must source the API from an FDA-registered supplier and follow USP Chapter 795 guidelines for non-sterile compounding [14].

Patients choosing a compounded formulation should verify the pharmacy holds an active Arizona State Board of Pharmacy license. The Board's license lookup tool at the Arizona State Board of Pharmacy website shows current standing for all licensed entities.

Transferring an Existing Addyi Prescription to Arizona

Flibanserin is not a federally scheduled controlled substance under the Controlled Substances Act, which simplifies interstate prescription transfers considerably. A patient moving to Arizona from another state may transfer an active flibanserin prescription to an Arizona-licensed pharmacy, provided: (1) the original prescription still has authorized refills remaining; (2) the receiving pharmacy is REMS-certified; and (3) the patient has a current, valid Patient-Prescriber Agreement on file with either the original or the receiving prescriber [2].

If the original prescription has expired or has no remaining refills, the patient needs a new evaluation from an Arizona-licensed prescriber. Telehealth platforms that hold multi-state licenses can often see a patient the same week and send a new prescription directly to an Arizona pharmacy.

What to Expect After Starting Flibanserin

Flibanserin's onset of benefit is gradual. The VIOLET trial (N=1,672) demonstrated that statistically significant improvement in satisfying sexual events compared with placebo emerged by week 4 but that the full treatment effect was better characterized at weeks 8 and 24 [15]. Patients should not judge efficacy at two weeks.

The most common adverse effects are dizziness (11.4% vs. 2.8% placebo), somnolence (11.2% vs. 3.0% placebo), nausea (10.4% vs. 3.9% placebo), and fatigue (9.2% vs. 5.5% placebo), as reported in the pooled analysis supporting FDA approval [1]. These effects are largely dose-dependent and are more pronounced when the drug is taken at times other than bedtime.

Alcohol is the most clinically significant interaction. Even moderate alcohol consumption within 2 hours of a flibanserin dose substantially increases the risk of severe hypotension and loss of consciousness [2]. The REMS program exists precisely because of three cases of syncope observed during the alcohol interaction study. Patients who cannot reliably abstain from alcohol are not appropriate candidates for flibanserin.

CYP3A4 inhibitors warrant special attention for Arizona patients using antifungals (fluconazole is commonly prescribed for vulvovaginal candidiasis), hormonal contraceptives containing certain progestins, or grapefruit products. Concomitant use of a strong CYP3A4 inhibitor and flibanserin is contraindicated in the label [2].

Monitoring and Follow-Up While on Flibanserin

After starting flibanserin, a structured follow-up at 4 weeks and 8 weeks is standard practice. At 8 weeks, the prescriber should document whether the patient reports a meaningful increase in satisfying sexual events or overall desire. The FDA label states that if no benefit is observed by 8 weeks of therapy, treatment should be discontinued [1].

Long-term safety data beyond one year are limited. The longest controlled trial supporting the approval ran 52 weeks. Post-marketing surveillance is ongoing, and prescribers are encouraged to report adverse events through FDA MedWatch [16]. No hepatotoxicity signal has emerged in post-marketing data as of the most recent FDA review, but periodic hepatic function reassessment is reasonable in patients with underlying liver risk factors [2].

Blood pressure monitoring at follow-up visits is advisable given the hypotension risk, particularly in patients who also use antihypertensive agents or moderate CYP2C19 inhibitors such as omeprazole [2].

Cost Reduction Strategies for Arizona Patients

Several concrete options exist for Arizona patients paying out of pocket or facing high PA hurdles.

Generic flibanserin became available in 2019 after Sprout's initial exclusivity period. Multiple manufacturers now supply the generic, and cash-pay prices at major Arizona pharmacies sit between $60 and $150 for a 30-day supply when a discount card is applied. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic flibanserin for significantly below retail.

The Addyi Complete Savings Program from Sprout Pharmaceuticals offers eligible commercially insured patients a co-pay reduction card. Patients on Medicare Part D are excluded from manufacturer co-pay programs under federal anti-kickback rules.

Some Arizona patients use HSA or FSA funds for flibanserin. Because it is an FDA-approved prescription medication, it qualifies as an eligible HSA/FSA expense under IRS Publication 502 [17].